Skip to main content
ELAB
NASDAQ Life Sciences

EL-32 Muscle Preservation Therapy Advances to Manufacturing Optimization

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.42
Mkt Cap
$9.277M
52W Low
$1.62
52W High
$466.2
52W Position info
235% above low
Off High info
99% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ELAB has more than doubled off its 52-week low of $1.62.

Summary

NorthStrive Biosciences, a wholly-owned subsidiary of PMGC Holdings Inc., announced the successful transfer of its EL-32 Working Cell Bank to a U.S. facility, initiating manufacturing optimization. This critical step aims to increase production yield and establish a cost-efficient, scalable process for EL-32, a dual myostatin asset targeting muscle preservation with GLP-1 therapies. This development marks a significant advancement for PMGC's life sciences segment, which has not been featured in recent news dominated by financing activities and new defense/aerospace subsidiaries. For a micro-cap company, this manufacturing milestone de-risks the product development pathway, moving EL-32 closer to investigational new drug (IND)-enabling activities and potential future commercialization. Investors should monitor further progress in manufacturing and any upcoming announcements regarding clinical development.

At the time of this announcement, ELAB was trading at $5.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $1.62 to $466.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.53 info
Change: -$0.050 (-3%) info
Market Cap: $1.279M info
ELAB
Nov 02, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.53 info
Change: -$0.590 (-28%) info
Market Cap: $1.279M info
ELAB
Oct 01, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.62
Real-time Price: $1.53 info
Change: -$2.09 (-58%) info
Market Cap: $1.279M info
ELAB
Sep 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.70
Real-time Price: $1.53 info
Change: -$3.17 (-67%) info
Market Cap: $1.279M info
ELAB
Sep 02, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $1.53 info
Change: -$3.67 (-71%) info
Market Cap: $1.279M info